Next-Gen Products Grow At Forest, Now Looking Past Saunders’ First 100 Days
This article was originally published in The Pink Sheet Daily
Forest’s total sales rose 24.9% year-over-year to $847 million, thanks largely to 59.4% growth by the specialty pharma’s so-called next-generation products.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.
Italy's Chiesi is looking to take a slice of Poland's consumer healthcare market by acquiring infant supplements specialist Smart Pharma.